RXST (RxSight) Valuation Rank


RXST RxSight Inc RXST
68 GF Score
Price $4.95
GF Value $35.80
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is RxSight Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

RxSight Valuation Rank Related Terms

RXST
68GF Score
RxSight Inc RXST
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is RxSight (RXST) Overvalued in 2026?

Based on GuruFocus' analysis, RxSight stock appears to be undervalued. The current stock price of $4.95 is trading 86.2% below its estimated GF Value™ of $35.80. GuruFocus considers RxSight to be Possible Value Trap.

Key valuation signals for RXST:

  • Valuation Rank:
  • GF Value™: $35.80 vs. price of $4.95 (86.2% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the RXST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RxSight Business Description

Address 100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
68GF Score

Get the complete analysis for RXST

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.95
Price
$35.80
GF Value